// App-Quantinova.ai

: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich rheumatoid arthritis, pre-rheumatoid arthritis and systemic lupus erythematosus

Researchers

Presenter

  • Suzanne Cole

Principal Investigators

  • Alice Walsh

  • Xuefeng Yin

  • Mihir Wechalekar

  • Malcolm Smith

  • Susanna M. Proudman

  • Douglas J. Veale

  • Ursula Fearon

  • Constantino Pitzalis

  • Christopher Chiu

  • Michael Sharp

  • John Alvarez

  • Ian Anderson

  • Loui Madakamutil

  • Sunil Nagpal

  • Yanxia Guo

Medical Centers

  • Janssen R&

  • Flinders University, Australia

  • Royal Adelaide Hospital, Adelaide, Australia

  • St. Vincent’s Univ. Hosp., Ireland

  • Queen Mary University of London, London, United Kingdom

Locations

  • Australia

  • Ireland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Lupus

  • Rheumatoid arthritis

  • Osteoarthritis

  • Inflammatory Arthritis

Biomarkers

  • Interferon regulatory factor 4

  • Peripheral blood mononuclear cell

  • TNF superfamily member 13b

  • X-Box Binding Protein 1

Drug/Treatment

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved